Entacapone increases and prolongs the central effects of L-DOPA in the 6-hydroxydopamine-lesioned rat

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 370, Issue 5, 2004, Pages 388-394

  Gerlach, Manfred ^a   Van Den Buuse, Maarten ^b   Blaha, Charles ^c,d   Bremen, Dirk ^e   Riederer, Peter ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c MACQUARIE UNIVERSITY   (Australia)

^d University of Memphis   (United States)

^e Orion Pharma GmbH   (Germany)

Author keywords

6 Hydroxydopamine; Catecholamine O methyltransferase inhibitors; Dyskinesia; Levodopa therapy; Parkinson therapy; Rotational behaviour; Voltammetry

Indexed keywords

6 HYDROXYTRYPTAMINE; BENSERAZIDE; ENTACAPONE; LEVODOPA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MEGADOSE; NONHUMAN; POTENTIOMETRY; RAT;

ANIMALS; CATECHOLS; CORPUS STRIATUM; DOPAMINE; DRUG SYNERGISM; LEVODOPA; MALE; OXIDOPAMINE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 11144254398     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-004-0984-8     Document Type: Article

References (22)

1. Andersson M, Hilbertson A, Cenci MA (1999) Striatal fosB expression is causally linked with L-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol Dis 6:461-474
2. Blaha CD (1996) Evaluation of stearate-graphite paste electrodes for chronic measurement of extracellular dopamine concentrations in the mammalian brain. Pharmacol Biochem Behav 55:351-364
3. Blaha CD, Jung ME (1991) Electrochemical evaluation of stearate modified graphite paste electrodes: selective detection of dopamine is maintained after exposure to brain tissue. J Electroanal Chem 310:317-334
4. Blaha CD, Phillips AG (1996) A critical assessment of electrochemical procedures applied to the measurement of dopamine and its metabolites during drug-induced and species-typical behaviours. Behav Pharmacol 7:675-708
5. Blaha CD, Lui D, Phillips AG (1996) Improved electrochemical properties of stearate-graphite paste electrodes after albumin and phospholipid treatments. Biosens Bioelectron 11:63-79
6. Cooper DR, Marrel C, Testa B, van de Waterbeemd H, Quinn N, Jenner P, Marsden CD (1984) L-Dopa methyl ester: a candidate for chronic systemic delivery of L-Dopa in Parkinson's disease. Clin Neuropharmacol 7:89-98
7. Dunah AW, Wang YH, Yasuda RP, Kameyama K, Huganir RL, Wolfe BB, Standaert DG (2000) Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. Mol Pharmacol 57:342-352
8. Gerlach M, Riederer P (1996) Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103:987-1041
9. Gerlach M, Xiao A-Y, Kuhn W, Lehnfeld R, Waldmeier P, Sontag K-H, Riederer P (2001) The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats. J Neural Transm 108:189-204
10. Henry B, Crossman AR, Brotchie JM (1998) Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp Neurol 151:334-342
11. Henry B, Crossman AR, Brotchie JM (1999) Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp Neurol 155:204-220
12. Jankovic JJ (2002) Therapeutic strategies in Parkinson's disease. In: Jankovic JJ, Tolosa E (eds) Parkinson's disease and movement disorders, 4th edn. Lippincott Williams and Wilkins, Philadelphia, pp 116-151
13. McNeely W, Davis R (1997) Entacapone. CNS Drugs 8:79-88
14. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN (1988) Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part II. Ann Neurol 24:372-378
15. Napolitano A, Bellini G, Borroni E, Zurcher G, Bonuccelli U (2003) Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats. Parkinson Relat Disord 9:145-150
16. Nissinen E, Lindén I-B, Schultz E, Pohto P (1992) Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn-Schmiedebergs Arch Pharmacol 346:262-266
17. Nutt JG (1987) On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. Ann Neurol 22:535-540
18. Paxinos G, Watson C (1997) The rat brain in stereotaxic coordinates, 3rd edn. Academic, New York
19. Sarre S, De Klipppel N, Herregodts P, Ebinger G, Michotte Y (1994) Biotransformation of locally applied L-dopa in the corpus striatum of the hemi-Parkinsonian rat studies with microdialysis. Naunyn-Schmiedebergs Arch Pharmacol 350:15-21
20. Smith LA, Jackson MJ, Hansard MJ, Maratos E, Jenner P (2003) Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naive MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure. Mov Disord 18:487-495
21. Spencer CM, Benfield P (1996) Tolcapone. CNS Drugs 5:475-481
22. Ungerstedt U, Arburthnott GW (1970) Quantitative recording of rotational behaviour in rats after 6-hydroxydopamine lesions in the nigrostriatal dopamine system. Brain Res 24:485-493